BioCentury | Aug 13, 2012
Company News

Astellas genitourinary news

...the research facility, which focused on lower urinary tract disorders, from Dynogen Pharmaceuticals Inc. in March 2006. Dynogen...
BioCentury | Feb 6, 2012
Company News

Edusa, Mitsubishi Tanabe Pharma deal

...testing for gastroesophageal reflux disease (GERD). Mitsubishi granted Dynogen Pharmaceuticals Inc. rights to the product in 2004. Dynogen...
...filed Chapter 7 bankruptcy in 2009. During the same year, Care Capital acquired most of Dynogen's...
BioCentury | Nov 9, 2009
Company News

Alnara management update

...Cambridge, Mass. Business: Metabolic, Inflammation Hired: Lee Brettman as CMO, formerly president and CEO of Dynogen Pharmaceuticals Inc. WIR...
BioCentury | Jun 8, 2009
Company News

PregLem management update

...Switzerland Business: Genitourinary, Endocrine Hired: Suhail Nurbhai as CMO, formerly VP of clinical development at Dynogen Pharmaceuticals Inc. WIR...
BioCentury | Mar 2, 2009
Company News

Dynogen gastrointestinal news

...Pharmaceuticals Inc. , Waltham, Mass. Business: Gastrointestinal Dynogen filed for Chapter 7 bankruptcy. Last year, Dynogen...
...acquisition by special purpose acquisition company Apex Bioventures Acquisition Corp. (NYSE-A:PEX, Hillsborough, Calif.) fell through. Dynogen's...
BioCentury | Oct 20, 2008
Finance

Ebb & Flow

...April, the SPAC called it quits on a reverse merger with gastrointestinal and genitourinary company Dynogen...
BioCentury | May 26, 2008
Clinical News

AA10021: Phase II data

...of placebo patients. Data were presented at the Digestive Disease Week meeting in San Diego. Dynogen...
...has rights to DDP225 from Mitsubishi under a 2003 deal (see BioCentury, Jan. 5, 2004). Dynogen Pharmaceuticals Inc....
BioCentury | May 26, 2008
Clinical News

AA10021: Phase IIb start

...This year, Dynogen will begin a double-blind, placebo-controlled, North American Phase llb trial of oral DDP225...
...oral DDP225. The company has rights to DDP225 from Mitsubishi (see BioCentury, Jan. 5, 2004). Dynogen Pharmaceuticals Inc....
BioCentury | Apr 21, 2008
Company News

Dynogen, Apex Bioventures Acquisition Corp. deal

...purpose acquisition company Apex and Dynogen terminated a deal under which Apex would have acquired Dynogen...
...conditions. Dynogen said it is planning a private financing this year (see BioCentury, Feb. 11). Dynogen Pharmaceuticals Inc....
BioCentury | Apr 21, 2008
Finance

Ebb & Flow

...of the combined company. Calling it quits Citing difficult market conditions, gastrointestinal and genitourinary company Dynogen...
...and special purpose acquisition company Apex Bioventures (AMEX:PEX) called off their reverse merger last week. Dynogen...
...February. The terms called for the acquisition to be for $98 million in stock, with Dynogen...
Items per page:
1 - 10 of 53
BioCentury | Aug 13, 2012
Company News

Astellas genitourinary news

...the research facility, which focused on lower urinary tract disorders, from Dynogen Pharmaceuticals Inc. in March 2006. Dynogen...
BioCentury | Feb 6, 2012
Company News

Edusa, Mitsubishi Tanabe Pharma deal

...testing for gastroesophageal reflux disease (GERD). Mitsubishi granted Dynogen Pharmaceuticals Inc. rights to the product in 2004. Dynogen...
...filed Chapter 7 bankruptcy in 2009. During the same year, Care Capital acquired most of Dynogen's...
BioCentury | Nov 9, 2009
Company News

Alnara management update

...Cambridge, Mass. Business: Metabolic, Inflammation Hired: Lee Brettman as CMO, formerly president and CEO of Dynogen Pharmaceuticals Inc. WIR...
BioCentury | Jun 8, 2009
Company News

PregLem management update

...Switzerland Business: Genitourinary, Endocrine Hired: Suhail Nurbhai as CMO, formerly VP of clinical development at Dynogen Pharmaceuticals Inc. WIR...
BioCentury | Mar 2, 2009
Company News

Dynogen gastrointestinal news

...Pharmaceuticals Inc. , Waltham, Mass. Business: Gastrointestinal Dynogen filed for Chapter 7 bankruptcy. Last year, Dynogen...
...acquisition by special purpose acquisition company Apex Bioventures Acquisition Corp. (NYSE-A:PEX, Hillsborough, Calif.) fell through. Dynogen's...
BioCentury | Oct 20, 2008
Finance

Ebb & Flow

...April, the SPAC called it quits on a reverse merger with gastrointestinal and genitourinary company Dynogen...
BioCentury | May 26, 2008
Clinical News

AA10021: Phase II data

...of placebo patients. Data were presented at the Digestive Disease Week meeting in San Diego. Dynogen...
...has rights to DDP225 from Mitsubishi under a 2003 deal (see BioCentury, Jan. 5, 2004). Dynogen Pharmaceuticals Inc....
BioCentury | May 26, 2008
Clinical News

AA10021: Phase IIb start

...This year, Dynogen will begin a double-blind, placebo-controlled, North American Phase llb trial of oral DDP225...
...oral DDP225. The company has rights to DDP225 from Mitsubishi (see BioCentury, Jan. 5, 2004). Dynogen Pharmaceuticals Inc....
BioCentury | Apr 21, 2008
Company News

Dynogen, Apex Bioventures Acquisition Corp. deal

...purpose acquisition company Apex and Dynogen terminated a deal under which Apex would have acquired Dynogen...
...conditions. Dynogen said it is planning a private financing this year (see BioCentury, Feb. 11). Dynogen Pharmaceuticals Inc....
BioCentury | Apr 21, 2008
Finance

Ebb & Flow

...of the combined company. Calling it quits Citing difficult market conditions, gastrointestinal and genitourinary company Dynogen...
...and special purpose acquisition company Apex Bioventures (AMEX:PEX) called off their reverse merger last week. Dynogen...
...February. The terms called for the acquisition to be for $98 million in stock, with Dynogen...
Items per page:
1 - 10 of 53